Syndicated Research Report Regenerative Medicine

Cell Therapy Technologies Market

Size, Share & Industry Analysis, By Type (Equipment, Consumables, Software and Other Technology Products), By Application (Human, Animal), By End User (Pharmaceutical and Biotechnology Companies, Research and Academic Institutes, Hospitals and Clinics), By Therapy Type (CAR-T and Other Engineered Immune Cells, Stem Cell Therapies, Other Cell Therapies), and Regional Forecast, 2026-2034

Report ID 24LS-8831
Pages 90
Last Updated
Author 24LifeSciences Research Team
Industry Regenerative Medicine
Starting from $995 USD

Market Overview

2025 Market SizeUSD 11.7 BnBase year
2026 EstimateUSD 12.7 BnEstimated year
2034 ForecastUSD 24.7 BnForecast value
CAGR8.7%2026–2034
Largest RegionNorth America2025

Cell Therapy Technologies Market Overview

The global Cell Therapy Technologies Market reached USD 11.7 billion in 2025, with an estimated USD 12.7 billion in 2026 and a projected USD 24.7 billion by 2034, equivalent to 8.7% CAGR for 2026–2034.

2025Base year for technology supplier revenueMarket scope
2025FDA approval of ZEVASKYN and other advanced therapiesFDA
2025Lonza Cocoon received FDA AMT designationLonza
2025Terumo BCT expanded automated T-cell manufacturing workflowsTerumo BCT

The cell therapy technologies market covers equipment, consumables, reagents and associated software sold for the isolation, engineering, expansion, characterization, preservation and release of living-cell medicinal products. It measures technology suppliers’ sales rather than the selling prices of CAR-T therapies or payments to contract manufacturers for patient doses. Dedicated clinical manufacturing systems and qualifying research products are included when purchased for cell-therapy workflows. General laboratory equipment used outside this application is excluded from the defined revenue boundary.

Cell-based therapies require viable starting material, traceable manipulation and batch-specific quality controls. FDA oversight extends to cellular therapies and related devices, while European advanced therapy rules impose manufacturing and pharmacovigilance requirements. The regulatory environment creates sustained demand for closed-system processing, single-use tubing, cell-culture reagents, flow cytometry and cryogenic handling. Purchases can occur during research, process validation and routine manufacturing, but each purchased product is counted once at the supplier transaction level.

Clinical translation supports equipment investment while consumables generate recurring purchases. Lonza received an FDA Advanced Manufacturing Technologies designation for its Cocoon platform in December 2025. Terumo Blood and Cell Technologies reported integrated activation, transduction and expansion workflows on its Quantum platform during 2025. BD introduced new spectral and imaging-enabled cell analysis instruments that year. These developments support automation and analytical consistency, although not every unit sold by the companies is attributable to cell therapy.

North America is the largest regional market because U.S. developers, research hospitals and technology vendors have established manufacturing networks. Europe combines established bioprocessing suppliers with a dedicated advanced-therapy regulatory framework. Asia-Pacific has active programs in Japan, China, South Korea, India and Australia, with procurement shaped by local manufacturing investment and regulatory requirements. Supplier competition centers on validated workflows, cell viability, batch traceability, service support and the lifetime cost of disposable materials.

Source: FDA cellular and gene therapy overview; Lonza Cocoon AMT designation; Terumo Quantum Flex announcement.

Key Takeaways: Cell Therapy Technologies Market

  • Base-year market size: Global cell therapy technology supplier revenue is modeled at USD 11.7 billion in 2025.
  • Forecast and CAGR: Revenue is projected to reach USD 24.7 billion by 2034, growing 8.7% annually from the 2026 estimate.
  • Leading type: Consumables accounted for an estimated 52% of 2025 revenue, reflecting recurring culture media, reagents and single-use supplies.
  • Leading application: Human applications represented an estimated 91% of 2025 revenue, led by clinical and translational cell-therapy workflows.
  • Largest region: North America accounted for an estimated 42% of 2025 revenue, supported by U.S. clinical manufacturing and research infrastructure.
  • Key growth drivers: Approved advanced therapies, closed processing, contamination control, automated cell expansion and increasingly detailed release testing support supplier demand.
  • Competitive landscape: Cytiva, Thermo Fisher Scientific, Sartorius, Lonza, Miltenyi Biotec, Terumo BCT and BD compete across overlapping equipment and consumables portfolios.
  • Coverage: The analysis spans Type, Application, End User and Therapy Type, with regional coverage of North America, Europe, Asia-Pacific, Latin America and Middle East & Africa.

Report Scope & Market Segmentation

The market measures third-party sales of instruments, cell-processing platforms, cell-culture and preservation materials, single-use products and associated software attributable to cell therapy development or manufacturing.

Report AttributeCoverage
Base Year2025
Estimated Year2026
Forecast Period2026–2034
Market MeasurementRevenue, USD million/billion
By TypeEquipment; Consumables; Software and Other Technology Products
By ApplicationHuman; Animal
By End UserPharmaceutical and Biotechnology Companies; Research and Academic Institutes; Hospitals and Clinics
By Therapy TypeCAR-T and Other Engineered Immune Cells; Stem Cell Therapies; Other Cell Therapies
By RegionNorth America; Europe; Asia-Pacific; Latin America; Middle East & Africa
Selected CountriesUnited States; Canada; Germany; United Kingdom; Japan; China; India; Brazil; Mexico; United Arab Emirates
Key Market PlayersDanaher Corporation (Cytiva); Thermo Fisher Scientific Inc.; Sartorius AG; Lonza Group AG; Miltenyi Biotec; Terumo Blood and Cell Technologies; Becton, Dickinson and Company; Merck KGaA; Corning Incorporated; STEMCELL Technologies Inc.; Bio-Techne Corporation; FUJIFILM Irvine Scientific

Market Definition & Revenue Boundaries

Products are counted at the point of external supplier sale and allocated to their primary intended cell-therapy use. Equipment includes closed processing instruments, bioreactors, sorters and qualified monitoring systems. Consumables include dedicated media, cytokines, bags, filters, tubing, sampling sets and cryopreservation reagents. Software and other technology products include separately sold workflow-control, manufacturing data and analytical applications; software bundled with an instrument remains in equipment revenue.

Human and animal applications are mutually exclusive by intended therapeutic species. End-user revenue is attributed to the purchasing organization rather than the eventual patient or sponsoring company, avoiding a second count when a hospital operates a sponsor-funded laboratory. Therapy-type allocations reflect the primary program supported by the purchased product. General-purpose products serving multiple therapeutic programs are assigned to their documented primary use, and finished drug revenue, CDMO service fees and unrelated gene-vector manufacturing sales are excluded.

Cell Therapy Technologies Market Dynamics

Approved cell therapies expand demand for controlled production

The FDA regulates cellular immunotherapies, hematopoietic products and certain devices used with advanced therapies. Its approved-product records include ZEVASKYN, an autologous gene-modified cell therapy approved in April 2025, and TECELRA, an engineered T-cell therapy approved in August 2024. Each marketed program requires documented handling, identity, potency and release testing. Manufacturers therefore purchase instruments and validated disposable assemblies beyond the initial clinical development phase. Supplier demand depends on the number of operating programs and their production intensity, not simply the list prices charged for individual patient treatments.

Closed manufacturing reduces contamination and handling risk

Autologous production often begins with a patient-specific cell collection, making batch identity and contamination prevention especially important. Cytiva describes the Sefia platform as digitally integrated closed systems for cell isolation, expansion and formulation. Lonza similarly positions Cocoon as an automated, functionally closed manufacturing system. These architectures replace transfers between open vessels with connected process steps and electronic records. The commercial effect is recurring demand for sterile tubing, single-use kits, qualified connectors and maintenance services, alongside instrument purchases when sites add manufacturing capacity or standardize existing processes.

Automation addresses workforce and process consistency constraints

Terumo BCT reported in November 2025 that University of Chicago researchers combined T-cell activation, transduction and expansion on Quantum Flex. The company described expansion from ten million starting cells to as many as nine billion over ten days in that experimental workflow. Such demonstrations do not establish routine commercial throughput for every therapy, but they show why developers evaluate integrated platforms. Integrated manufacturing systems can reduce repeated manual interventions and simplify operator training across cell processing steps. Equipment vendors compete on cell recovery, repeatability, validated protocols and the ability to transfer processes between clinical sites without changing product characteristics.

Analytical testing remains a recurring procurement category

Cell identity, viability, purity and phenotype must be assessed before critical manufacturing decisions. BD introduced its FACSDiscover A8 analyzer in May 2025 with spectral flow cytometry and real-time imaging capabilities. The instrument is applicable to several scientific disciplines, so only its cell-therapy-attributable sales belong in this market. Even so, expanding immunophenotyping requirements support purchases of antibodies, reference controls, sample preparation products and analytical software. Buyers compare assay reproducibility, data management, instrument uptime and compatibility with existing quality systems when selecting technology suppliers.

Cost and regulatory burden limit smaller manufacturing programs

Advanced cell therapies require specialized facilities, cold-chain coordination, trained personnel and qualified manufacturing controls. The European Medicines Agency warns that unauthorized advanced therapies may be marketed outside legitimate clinical trials, and advises patients to verify regulatory authorization before treatment. New entrants must budget for process validation, equipment qualification and ongoing release assays before patient-scale revenues emerge. These requirements can delay equipment orders or encourage outsourcing rather than facility ownership. Suppliers offering modular systems, application support and standardized disposable workflows can reduce implementation complexity, but they cannot remove the need for product-specific validation.

Sources: FDA cellular and gene therapy program; FDA RMAT approval records; Cytiva; Lonza; Terumo BCT; BD; European Medicines Agency.

Cell Processing & Manufacturing Technology

Manufacturing technology is selected according to the cell source, manipulation steps, clinical development stage and release specification. Autologous programs prioritize chain-of-identity and patient-specific processing, while allogeneic programs may emphasize scalable expansion and cryogenic inventory. Cell therapy suppliers offer both dedicated equipment and recurring materials, with software providing traceability and process integration.

WorkflowRepresentative technologySupplier examplePrimary procurement requirement
Cell isolationAutomated separation and collectionCytiva Sefia SelectRecovery and closed transfer
Cell expansionHollow-fiber bioreactor and mediaTerumo Quantum FlexConsistent viable-cell output
Manufacturing automationClosed processing platformLonza CocoonQualified end-to-end protocols
Cell characterizationSpectral flow cytometryBD FACSDiscover A8Phenotype and reproducibility
Cell preservationFreezing media and storage assembliesSartorius cell preservation portfolioViability and transport control

Autologous cell therapy programs require traceable manufacturing records for each patient-specific starting material and finished product. The FDA approval of engineered immune-cell products has established a regulated setting in which collection material, manipulation steps and finished product identity must be controlled. Closed-system processing can help reduce open handling, but a platform is not itself a therapy approval. A manufacturer must still demonstrate that its particular process consistently yields a product meeting specifications. This distinction matters commercially because equipment adoption is influenced by validation costs as much as by nominal throughput.

Allogeneic approaches may require larger expansion batches and inventory management. Sartorius supplies cell culture media, bioreactors and preservation materials that support different stages of process development. Terumo BCT and FUJIFILM Irvine Scientific have paired expansion hardware with a defined T-cell medium, showing how vendors coordinate consumable compatibility. Purchasers must still account for donor variability, cell phenotype and freezing recovery, making analytical instruments and qualified reagents recurring expenditure categories across development stages.

Quality-control requirements connect upstream cell processing with downstream release decisions. BD instruments can measure cell phenotypes, while digitally integrated systems can associate production data with specific lots. The strongest purchasing rationale arises when a technology improves repeatability, traceability or workflow control without changing critical product attributes. Facilities running several therapies often require configurable protocols and independent quality review. This favors suppliers that provide service support, documentation and validated interfaces rather than relying solely on equipment specifications.

Cell Therapy Technologies Market Segmentation by Type

Report Segmentation
By Type

Cell therapy technology products are grouped by their primary commercial form into Equipment, Consumables and Software and Other Technology Products. Consumables lead because clinical and research operations repeatedly purchase culture media, tubing, reagents and disposable assemblies. Instruments typically require larger individual capital approvals, while software revenue depends on whether digital functionality is sold separately or bundled with a system.

Leading type

Consumables

Dedicated cell-culture media, cytokines, single-use bags, sterile connectors and preservation reagents are consumed during manufacturing runs. Sartorius and Thermo Fisher supply several of these categories, while Corning provides culture and expansion materials. Repeat purchasing supports a larger annual revenue contribution than a one-time instrument installation, particularly as commercial manufacturing volumes increase.

Capital equipment

Equipment

Closed cell processing systems, automated bioreactors, cell analyzers and sorters account for major site investments. Lonza Cocoon, Terumo Quantum Flex, BD FACSDiscover and Cytiva Sefia demonstrate distinct purchasing decisions within the category. Equipment sales are assigned by the buyer’s primary cell-therapy application, avoiding inclusion of all general laboratory instrument revenue.

Digital and ancillary

Software and Other Technology Products

Separately licensed manufacturing execution, process monitoring and analytical software supports audit trails and batch review. Cytiva Chronicle exemplifies software associated with cell manufacturing equipment. Bundled control applications remain in the price of the associated instrument, preventing a second allocation to software. Other qualified technology products are included only when sold independently for cell-therapy operations.

Consumables represented an estimated 52% of 2025 market revenue. Equipment purchases respond to manufacturing capacity expansion, while recurring media, assay and single-use orders follow the number of production runs. The classification is based on supplier invoice category rather than counting an instrument and its embedded software separately.

Cell Therapy Technologies Market Segmentation by Application

Report Segmentation
By Application

Application assigns each technology purchase to Human or Animal therapeutic development. Human programs account for most demand because marketed immune-cell products, academic translational research and industrial manufacturing facilities require validated tools. Animal applications include veterinary cell therapy and animal-specific development, but products used solely as preclinical models for human therapies remain in the human category.

Leading application

Human

The FDA regulates commercial human cell therapies and related devices, while EMA oversees advanced therapy medicinal products in Europe. CAR-T and other engineered-cell developers use closed processing, cell expansion and quality-control systems to meet product-specific requirements. Human use includes research and clinical manufacturing where the intended final therapy is administered to people.

Specialized application

Animal

Veterinary and animal-specific cell programs use culture media, separation equipment and preservation products. Some laboratory tools are shared with human research, but revenue is attributed by the buyer’s documented therapeutic objective. This category does not include all animal-model experimentation performed to support human medicines, which would inflate the veterinary technology revenue boundary.

Cross-application controls

Dedicated attribution

Multifunction instruments may support both human and animal programs in a research center. Allocation follows the primary validated workflow or documented procurement purpose. A shared instrument is not counted twice simply because it processes several cell types, and unrelated diagnostic or agricultural applications remain outside the therapeutic market.

Human applications represented an estimated 91% of 2025 market revenue. The smaller animal category is supported by veterinary research and therapy programs but lacks the same density of commercial advanced-therapy manufacturing infrastructure. Application shares describe end-use attribution, not the relative prevalence of disease in people and animals.

Cell Therapy Technologies Market Segmentation by End User

Report Segmentation
By End User

End users are assigned by the organization that purchases the technology: Pharmaceutical and Biotechnology Companies, Research and Academic Institutes, or Hospitals and Clinics. The purchaser-based rule avoids counting the same platform twice when a pharmaceutical sponsor finances equipment operated by a partner institution. Technology suppliers often serve all three channels through different sales, training and support arrangements.

Largest customer group

Pharmaceutical and Biotechnology Companies

Developers and commercial manufacturers buy qualified cell processing systems, recurring materials and process-control software. Their spending is linked to technology transfer, validation and routine production, with supplier contracts often extending across multiple manufacturing campaigns. Companies may outsource physical manufacturing, but only direct technology purchases by the designated buyer are attributed to this channel.

Translational research

Research and Academic Institutes

Universities and research hospitals conduct early cell engineering, phenotype analysis and manufacturing method development. The University of Chicago’s 2025 Quantum Flex demonstration illustrates how academic groups evaluate integrated processing workflows. Research budgets often favor flexible systems capable of serving several projects, whereas commercial facilities place greater weight on locked protocols and audit documentation.

Clinical production

Hospitals and Clinics

Hospital-based cellular therapy units may handle collection, manipulation, cryopreservation and quality testing, depending on their authorization and capabilities. These facilities require trained staff and validated instruments to support patient-specific workflows. Where a hospital buys equipment directly, its purchase is assigned to this channel even if a pharmaceutical manufacturer sponsors the related clinical study.

Pharmaceutical and biotechnology buyers remain the leading end-user channel because manufacturing scale-up and regulatory validation require sustained capital and consumable expenditure. Academic facilities remain important technology test sites, while hospital demand concentrates in clinical collection, processing and administration support. The end-user categories are mutually exclusive because each technology sale is assigned to the organization named on the purchase record.

Cell Therapy Technologies Market Segmentation by Therapy Type

Report Segmentation
By Therapy Type

Therapy Type divides cell-therapy technology demand by the primary therapeutic program supported: CAR-T and Other Engineered Immune Cells, Stem Cell Therapies, and Other Cell Therapies. This axis replaces an overlapping technology classification that would otherwise count single-use materials again within cell processing and preservation. A multipurpose purchase is assigned to one primary program according to the buyer’s validated application.

Engineered immune-cell workflows

CAR-T and Other Engineered Immune Cells

CAR-T and engineered T-cell programs require cell selection, activation, gene delivery, expansion, formulation and phenotype testing. FDA approvals of engineered immune-cell products demonstrate the commercial manufacturing setting. The category includes TCR-T and related engineered immune-cell approaches when they are not separately counted as stem-cell therapies.

Regenerative programs

Stem Cell Therapies

Stem-cell programs use expansion media, differentiation reagents, characterization assays and cryogenic materials. Research and clinical activities span hematopoietic and other stem-cell applications, with product-specific regulatory obligations. Technologies bought for these programs are counted here only when the intended therapeutic material is a stem-cell product rather than an engineered immune-cell medicine.

Additional modalities

Other Cell Therapies

This group includes unmodified immune-cell products, selected tissue-derived cellular therapies and other cell-based treatments outside the first two categories. Processing needs vary substantially by source material and administration route. Suppliers therefore sell application-specific consumables and configurable equipment, while quality-control systems must still meet the product’s validated identity and potency requirements.

CAR-T and related engineered immune-cell workflows are an important driver of advanced automation purchases, while stem-cell applications support substantial demand for culture and preservation supplies. Therapy-type allocation is made once per technology sale, avoiding a second count when the same equipment can serve multiple modalities.

Cell Therapy Technologies Market Regional Analysis

Regional demand follows the location of cell-therapy development, manufacturing facilities, academic laboratories and qualified technology distributors. Supplier sales are attributed to the region where the product is purchased for therapeutic use, rather than the eventual country of patient treatment.

North America

Largest market - 2025 leading region

North America accounts for an estimated 42% of 2025 cell therapy technology revenue. U.S. manufacturers and academic centers purchase closed processing platforms, GMP-grade media and release-testing instruments for autologous and allogeneic programs. FDA regulation of cellular and gene therapy products makes documented process control a central procurement requirement. The agency’s approval record includes ZEVASKYN and TECELRA, reflecting the diversity of cell-based modalities that rely on different manufacturing tools. Technology demand extends beyond product launches because facilities must qualify instruments, replace disposables and maintain validated processes during clinical development. Canada contributes academic research and specialized biomanufacturing activity, although its procurement volume is smaller than that of the United States. Supplier presence from Cytiva, Thermo Fisher, BD and other vendors supports equipment installation and after-sales service. Regional buyers compare total process cost, contamination controls, cell recovery and the ability to link manufacturing data with quality records. The high density of translational programs supports demand for flexible analytical systems as well as dedicated clinical manufacturing equipment.

Priority country signals

United States

Selected market signal

FDA’s cellular and gene therapy program oversees products that include engineered immune cells and related manufacturing technologies. Its RMAT approval record lists ZEVASKYN and TECELRA among approved advanced therapies. U.S. developers consequently invest in closed processing, cell characterization and qualified reagents throughout clinical and commercial manufacturing. University of Chicago researchers also reported an integrated T-cell receptor manufacturing workflow with Terumo BCT in November 2025, demonstrating continued academic evaluation of automated platforms.

Source: FDA.

Europe

Established market - Advanced therapy regulation and suppliers

Europe combines a formal advanced therapy medicinal product framework with manufacturers of bioprocess equipment and consumables. EMA authorization requirements influence facility design, quality documentation and product release practices. Lonza announced in December 2025 that the FDA granted its Cocoon platform an Advanced Manufacturing Technologies designation, demonstrating the cross-border relevance of European technology suppliers. Sartorius provides cell culture media, disposable processing products and preservation materials for research through commercial production. European demand spans pharmaceutical manufacturing, contract development facilities, academic centers and hospital-associated cell processing. Procurement may be slowed by capital budgets and differing national reimbursement decisions, even where a product has European marketing authorization. The EMA’s 2025 authorization of Aucatzyl added an advanced immune-cell therapy to the European regulatory landscape. Demand for qualified consumables is less dependent on one-off instrument procurement because active manufacturing campaigns require repeated supply. Regional customers increasingly seek systems that simplify operator training and documentation while retaining flexibility for product-specific validation.

Priority country signals

Germany

Selected market signal

Sartorius supplies GMP-oriented media, cell-processing technologies, single-use assemblies and freezing solutions used in advanced therapy workflows. German biotechnology and academic customers therefore have access to both specialized consumables and broader bioprocess infrastructure. European advanced-therapy regulation requires product-specific quality evidence, so supplier documentation and equipment qualification remain important in procurement decisions. Media selection and cell viability testing also influence the transfer of research methods into clinical manufacturing.

Source: Sartorius.

Asia-Pacific

Expanding capability - Research and manufacturing investment

Asia-Pacific demand reflects investments in cell therapy research, laboratory automation and domestic manufacturing infrastructure. Japan regulates regenerative medical products through a dedicated product-information framework, while China and South Korea maintain active development programs. India has expanded access to advanced analytical instruments, with BD reporting a FACSDiscover S8 installation at IIT Jodhpur in 2023. These installations create service and reagent demand as research laboratories adopt higher-dimensional cell analysis. Buyers in the region balance import costs, local technical support and regulatory qualification requirements. Commercial manufacturing programs can support purchases of cell expansion systems and closed single-use kits, whereas university laboratories frequently prioritize flexible research configurations. Regional demand is diverse: Japanese programs place emphasis on documented regulatory pathways, Chinese developers have broad domestic manufacturing capacity, and Indian academic centers are strengthening translational research infrastructure. The rate at which new projects convert to repeat consumable orders depends on clinical progression and sustained facility funding.

Priority country signals

Japan

Selected market signal

Japan’s Pharmaceuticals and Medical Devices Agency provides product information and safety materials for regenerative medical products. That regulatory structure supports demand for controlled cell processing and quality documentation where therapeutic programs advance. Manufacturers serving Japanese customers must address local technical support, product registration and validated manufacturing requirements. Academic laboratories also purchase analytical and culture equipment, but not every general research sale is counted within therapeutic technology revenue.

Source: PMDA.

Latin America

Developing market - Specialized clinical infrastructure

Latin American cell therapy technology purchasing is concentrated in major research institutions, specialized hospitals and selected commercial manufacturing programs. Brazil has authorized advanced cellular therapies and maintains post-authorization monitoring of their safety and effectiveness. Anvisa reported in January 2025 that monitoring documents cover advanced therapies registered in Brazil since 2020. This framework creates demand for reliable collection, manipulation and traceability tools, particularly where patient-specific products require tightly coordinated handling. Technology purchases remain constrained by import expenses, funding availability and limited access to experienced maintenance personnel. Laboratories may use shared instruments across several programs, so only attributable cell-therapy usage is included in the revenue boundary. Suppliers offering training, consumable availability and validated protocols are better positioned to serve facilities with smaller production volumes. Mexico and other regional markets contribute research and clinical activity, but widespread commercial cell manufacturing remains less developed than in North America and Europe. Growth depends on stable procurement budgets and expansion of qualified treatment centers.

Priority country signals

Brazil

Selected market signal

Anvisa’s January 2025 announcement describes periodic monitoring reports for registered advanced therapy products. Brazilian clinical programs therefore operate within a framework that evaluates safety and effectiveness after authorization. Technology demand includes cell handling, sterile consumables, cryopreservation and traceability systems used by qualified facilities. Equipment suppliers must also address import logistics and technical support, since service delays can disrupt time-sensitive cell processing and quality-control operations.

Source: Anvisa.

Middle East & Africa

Early-stage market - Specialist centers and training

The Middle East and Africa market is smaller because advanced cell manufacturing facilities and specialized quality-control laboratories are concentrated in a limited number of healthcare and research hubs. Procurement is typically associated with academic programs, tertiary hospitals and biopharmaceutical investment rather than broad routine clinical use. Facilities considering autologous therapies require collection coordination, cell preservation and identity tracking in addition to dedicated processing equipment. Imports of validated media and single-use assemblies can create lead-time and storage challenges. Suppliers with regional service partners and reliable cold-chain distribution may have an advantage over vendors offering equipment without continuing technical support. Demand also depends on the availability of trained cell-processing personnel and the ability to maintain cleanroom and testing infrastructure. In markets where manufacturing remains centralized abroad, local purchases may focus on collection, characterization and preservation instead of full-scale cell expansion. The revenue boundary excludes general hospital laboratory equipment not demonstrably used for cell therapy programs.

Priority country signals

United Arab Emirates

Selected market signal

Specialist hospitals and biotechnology programs in the United Arab Emirates can procure cell characterization and preservation technologies for research and patient-specific workflows. Facility-level adoption depends on qualified personnel, controlled sample handling and reliable reagent supply. Where therapeutic products are manufactured outside the country, local technology demand may be concentrated in collection and logistics rather than full production. No unverified national market-size or approval figures are assigned to this country.

Source: FDA manufacturing context.

Regulatory Controls & Manufacturing Standards

Cell therapy technology purchasing is closely tied to manufacturing controls and the regulatory status of the intended therapeutic product. Regulatory authorization applies to the medicine, not automatically to every instrument used in its production. Technology vendors can nevertheless obtain designations or publish validation information that helps manufacturers evaluate platform suitability.

Authority or eventDateVerified scopeProcurement implication
FDA ZEVASKYN approvalApril 2025Autologous gene-modified cell therapyValidated manipulation and release testing
EMA Aucatzyl authorizationJuly 2025Engineered T-cell therapyATMP manufacturing controls
Lonza Cocoon AMT designationDecember 2025Automated manufacturing platform designationPlatform evaluation and qualification
FDA cellular therapy programCurrentRegulation of cellular therapies and related devicesQuality systems and traceability

FDA approval records distinguish between cellular therapies and the tools used to manufacture them. An approved cell therapy still requires process-specific qualification of equipment, raw materials and analytical methods. Technology buyers therefore request documentation on material quality, software traceability and the reproducibility of cell recovery. Closed processing may lower contamination exposure, but product identity and potency requirements remain specific to the individual therapeutic program. This regulatory distinction prevents technology vendors from presenting a platform designation as approval of a medicine.

EMA classifies eligible cell and gene medicines as advanced therapy medicinal products and issues product-specific authorization decisions. The agency granted Aucatzyl a conditional marketing authorization in July 2025. That decision supports a commercial context for engineered T-cell manufacturing in Europe, but it does not establish that every research program or processing technology is authorized. The EMA also warned in March 2025 against unregulated advanced therapies, highlighting the importance of verified clinical and manufacturing status.

Lonza reported that the FDA granted Cocoon an Advanced Manufacturing Technologies designation in December 2025. The designation can help developers evaluate advanced manufacturing approaches and may reduce uncertainty during regulatory engagement. It does not replace therapy-specific clinical evidence or eliminate facility qualification. Suppliers serving regulated cell therapy programs must still support customers with change control, validated materials and reliable technical documentation throughout process development and commercial supply.

Competitive Landscape

Competition spans diversified life-science suppliers and specialists in cell processing, culture media, analytics and preservation. Danaher participates through Cytiva, while Thermo Fisher, Sartorius, Lonza, Miltenyi Biotec, Terumo BCT and BD serve different manufacturing stages. Buyers often qualify more than one vendor because cell isolation, expansion, testing and storage impose distinct technical requirements. The market is therefore fragmented by workflow despite the presence of large diversified suppliers.

Integrated bioprocessing

Cytiva and Thermo Fisher

Cytiva combines Sefia processing and Chronicle software, while Thermo Fisher supplies CTS Rotea and cell therapy materials. Both suppliers serve research-to-manufacturing transitions with instruments and recurring materials used in cell processing workflows.

Closed automation

Lonza and Terumo BCT

Lonza Cocoon and Terumo Quantum Flex illustrate integrated cell manufacturing approaches. Adoption depends on product-specific validation, process compatibility and local service support.

Analytics and separation

BD and Miltenyi Biotec

BD develops flow cytometry instruments and reagents; Miltenyi supplies separation and automated processing technologies. Quality-control workflows require ongoing purchases of cell staining reagents, controls and instrument maintenance services.

Culture and preservation

Sartorius and Corning

Sartorius provides GMP-grade media and single-use solutions, while Corning offers culture and expansion systems. Recurring consumable orders depend on the number of active manufacturing campaigns and the specific materials validated for each therapy.

Integrated suppliers compete through portfolio breadth and compatibility across instruments, consumables and data systems. Cytiva’s Sefia platform connects isolation, expansion and formulation operations, while Thermo Fisher’s CTS Rotea supports closed cell separation and concentration. These capabilities can reduce the number of interfaces a manufacturer must qualify. Buyers still evaluate each platform against their specific starting material, cell phenotype and production scale. Vendor lock-in is moderated by the need for independently validated materials and by the availability of specialized suppliers for critical steps.

Specialist vendors compete on cell recovery, assay performance, preservation reliability and documented application-specific protocols. Miltenyi Biotec offers cell separation and automated manufacturing technologies; BD supplies advanced flow cytometry instruments and associated reagents. Terumo BCT’s Quantum Flex and Lonza’s Cocoon focus on automated processing, with published development work supporting adoption discussions. Sartorius and Corning compete in media, culture systems and single-use products. Each product family may be used outside therapeutic manufacturing, so only attributable cell-therapy sales are included in the modeled market.

Customer decisions depend on reproducibility, GMP documentation, training, technical service and consumable availability. A platform may be attractive in early development yet require additional process comparability work before commercial deployment. Manufacturers often retain established systems after validation because changing equipment or raw materials can trigger substantial requalification. This creates opportunities for recurring reagent and disposable supply, while new instrument sales are sensitive to capital spending cycles and facility construction timelines.

Key Companies Profiled

  • Danaher Corporation (Cytiva)
  • Thermo Fisher Scientific Inc.
  • Sartorius AG
  • Lonza Group AG
  • Miltenyi Biotec
  • Terumo Blood and Cell Technologies
  • Becton, Dickinson and Company
  • Merck KGaA
  • Corning Incorporated
  • STEMCELL Technologies Inc.
  • Bio-Techne Corporation
  • FUJIFILM Irvine Scientific

Recent Developments in the Cell Therapy Technologies Market

December 2025: Lonza announced that its Cocoon cell therapy manufacturing platform received an FDA Advanced Manufacturing Technologies designation. The company described a functionally closed and automated system with configurable protocols. The designation may help manufacturers assess platform qualification, but it is not a regulatory approval for any specific cell therapy product or clinical manufacturing protocol. Source

December 2025: BD introduced additional FACSDiscover A8 analyzer configurations with three- and four-laser options. The launch broadened access to spectral cytometry and real-time imaging across laboratory budgets. The instruments support immunology and cell characterization research, with therapeutic-market attribution limited to purchases serving cell therapy workflows and documented translational manufacturing programs. Source

November 2025: Terumo BCT reported a University of Chicago collaboration demonstrating activation, transduction and expansion of TCR-T cells on Quantum Flex. Researchers reported expansion to as many as nine billion cells over ten days. The work supports evaluation of integrated workflows, without establishing commercial performance for every therapy. Source

July 2025: The European Medicines Agency recorded conditional authorization of Aucatzyl for eligible adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. The authorization adds a regulated European engineered-cell therapy and reinforces demand for validated cell manufacturing, testing and release processes at qualified facilities serving eligible patients. Source

June 2025: Terumo BCT published an integrated CAR-T manufacturing workflow using its Quantum system, combining activation, transduction and expansion. The company reported consistent production exceeding twelve billion cells within seven to eight days in its study. The protocol illustrates continuing efforts to reduce manual processing steps and standardize production. Source

May 2025: BD launched the FACSDiscover A8 analyzer with spectral and real-time cell imaging technologies. The company positioned the instrument for research and translational applications, including immuno-oncology. Its launch expands analytical options for laboratories characterizing cells, although the device also serves nontherapeutic scientific applications outside the cell therapy revenue boundary. Source

Market Outlook, 2026–2034

The Cell Therapy Technologies Market is projected to grow from USD 12.7 billion in 2026 to USD 24.7 billion by 2034, a 8.7% CAGR. Expansion reflects recurring cell-culture materials, adoption of closed manufacturing systems and investment in analytical controls.

Market variable2026 starting position2034 demand direction
ConsumablesRecurring media and single-use purchasesIncrease with active manufacturing runs
AutomationClinical and commercial platform validationGreater use of integrated processing
AnalyticsFlow cytometry and release testingHigher traceability and assay demand
Geographic expansionEstablished North American and European hubsAdditional Asia-Pacific capacity
Procurement riskCapital and regulatory qualification costsContinued validation-related spending

Consumables should remain the largest revenue category because every cell therapy manufacturing campaign requires qualified materials, while instruments can remain in service across many batches. Media, cytokines, tubing, sampling sets and freezing products therefore provide a recurring revenue base. The extent of growth depends on commercial production volumes and the number of active clinical programs. Manufacturers may also reduce consumption per batch through process optimization, so supplier sales need not increase at exactly the same pace as treated-patient numbers.

Equipment purchases will be influenced by facility additions, automation replacement cycles and the transfer of clinical protocols to commercial operations. Integrated platforms may shorten manual handling, but developers must demonstrate that process changes preserve product quality. The December 2025 Lonza Cocoon designation and Terumo BCT workflow publications provide examples of technology development rather than guarantees of universal adoption. Buyers will continue comparing platform flexibility, service coverage, consumable cost and qualification documentation.

Analytical and digital technologies should gain importance as manufacturers standardize cell characterization and batch records. BD’s spectral and imaging instruments and Cytiva’s Chronicle manufacturing software illustrate the range of tools involved. Separately priced software remains a smaller revenue category than equipment or consumables, but interoperability can influence purchasing decisions across the workflow. Systems that connect production data with quality review may help facilities handle patient-specific batch records and reduce transcription errors.

North America is expected to retain the largest regional revenue base, supported by established U.S. clinical manufacturing and research networks. Europe benefits from regulated advanced therapy programs and equipment suppliers, while Asia-Pacific can expand through domestic research and manufacturing investments. The main constraints remain capital costs, regulatory validation, skilled labor and supply reliability for critical materials. Competition is likely to favor suppliers that can document consistent performance and maintain dependable consumable deliveries across multiple facilities.

Report Coverage

The report covers commercial technology suppliers, qualified cell-processing workflows and attributable end-user purchases across five regions.

Market sizing2025 base, 2026 estimate, 2034 forecast and CAGR.
Product analysisEquipment, consumables and separately sold digital technology.
ApplicationHuman and animal therapeutic workflows.
End usersBiopharma companies, research institutes, hospitals and clinics.
Regional analysisFive regions and priority country-level operating factors.
Competitive landscapePlatform, reagent and analytical suppliers with verified products.

Frequently Asked Questions

How large is the Cell Therapy Technologies Market?

The global market is modeled at USD 11.7 billion in 2025 and USD 12.7 billion in 2026, reaching USD 24.7 billion in 2034. The figures cover technology suppliers’ attributable equipment, consumables and software sales, rather than revenues from finished cell therapies or contract manufacturing services.

What is the CAGR for cell therapy technologies through 2034?

The normalized 2026–2034 compound annual growth rate is 8.7%. Growth is supported by manufacturing automation, recurring cell-culture materials, clinical program expansion and analytical quality controls. The rate is calculated from the 2026 estimate and 2034 forecast using eight annual periods.

Which region leads the cell therapy technologies market?

North America is the largest regional market, with an estimated 42% of 2025 revenue. The United States combines advanced-therapy developers, academic manufacturing centers and major technology suppliers. Europe and Asia-Pacific also contribute substantial demand through regulated manufacturing and research investment.

Which product type has the largest cell therapy technology share?

Consumables lead with an estimated 52% of 2025 revenue. Culture media, cytokines, sterile tubing, disposable bags and preservation reagents are repeatedly purchased during clinical and commercial manufacturing. Instruments generally require larger one-time capital expenditures and remain in service over several production campaigns.

What is included in cell therapy manufacturing equipment?

The equipment category includes cell separation instruments, closed processing platforms, automated bioreactors, cell analyzers and qualified preservation systems. Examples include Cytiva Sefia, Lonza Cocoon and Terumo Quantum Flex. Sales are included only when attributable to cell-therapy development or manufacturing.

Why are single-use technologies important for CAR-T production?

Single-use tubing, bags and sterile connectors can reduce open handling and cleaning between patient-specific manufacturing batches. They also support closed processing architectures used in CAR-T production. Manufacturers must still validate the complete process, and disposable components create recurring supply and waste-management obligations.

What role does flow cytometry play in cell therapy?

Flow cytometry helps characterize cell identity, phenotype and purity during development and quality control. BD’s FACSDiscover instruments offer spectral and imaging capabilities. The same analyzers can support other research applications, so only their documented cell-therapy use belongs within this market.

How do cell therapy technologies differ from cell therapy drugs?

Technology revenue comes from selling equipment, materials and software used to develop or manufacture living-cell medicines. Finished cell therapy drug revenue reflects the sale of patient-ready medicines and is excluded from technology supplier revenue. Counting both as technology revenue would duplicate value and overstate the market, so finished therapies and unrelated CDMO service fees are excluded.

Which companies supply cell therapy manufacturing technologies?

Relevant suppliers include Cytiva, Thermo Fisher Scientific, Sartorius, Lonza, Miltenyi Biotec, Terumo BCT, BD, Merck KGaA and Corning. Their portfolios cover cell isolation, culture, expansion, analytics, preservation and workflow software. Product qualification records, technical service coverage and the availability of validated replacement parts influence supplier selection.

What are the main constraints on cell therapy technology adoption?

Capital investment, GMP qualification, skilled staffing, process comparability and reliable consumable supply constrain adoption. Each cell therapy requires product-specific validation even when a processing platform has established technical capabilities. Smaller programs may use shared facilities or external manufacturers rather than buying a complete production line.

Research Sources & Evidence Base

View research sources used for this overview
  1. FDA. Cellular and gene therapy products.
  2. FDA. RMAT approval records, September 2025.
  3. European Medicines Agency. Advanced therapy medicinal products overview.
  4. European Medicines Agency. Aucatzyl authorization record, July 2025.
  5. Lonza Group. Cocoon AMT designation, December 2025.
  6. Terumo BCT. University of Chicago Quantum Flex TCR-T workflow, November 2025.
  7. Terumo BCT. Integrated Quantum CAR-T manufacturing protocol, June 2025.
  8. Terumo BCT. Collaboration with FUJIFILM Irvine Scientific, January 2025.
  9. BD. FACSDiscover A8 global launch, May 2025.
  10. BD. FACSDiscover A8 expanded configurations, December 2025.
  11. BD. First image-enabled spectral cell sorter in India, November 2023.
  12. Cytiva. Sefia cell therapy manufacturing platform.
  13. Thermo Fisher Scientific. Cell and gene therapy manufacturing solutions.
  14. Sartorius. Cell therapy product solutions.
  15. Danaher. Bioprocessing technologies and cell therapies.
  16. Corning. Bioprocessing application products.
  17. NIH. Engineering immune cells within the body, July 2025.
  18. PMDA Japan. Regenerative medical product information.
  19. Anvisa Brazil. Monitoring of advanced therapy products, January 2025.
  20. National Library of Medicine. Automated manufacturing of cell therapies, February 2025.
  21. Miltenyi Biomedicine. CliniMACS Prodigy manufacturing technology.
Trusted collaboration

Supporting teams across the life-sciences ecosystem

Focused market intelligence for commercial, strategy, product, and research teams across healthcare and life sciences.

Bain
Deloitte
PwC
Commercial Healthcare Partners
Client logo
Client logo
Life-sciences market focus Clear scope and sample review Confidential enquiry support

Display logos only where use is approved. A logo does not imply a public endorsement.

Client feedback

What teams value in their research experience

Feedback from research engagements, with client identities omitted where confidentiality applies.

Publish named testimonials only when the individual and organization have approved disclosure.

Research transparency

Built on a clearly defined research framework

Review the report scope, forecast timeframe, methodology, and cited evidence before deciding whether the full study fits your requirement.

Defined Market Scope

Coverage, segmentation, geography, and market boundaries are stated within the report.

Evidence-Led Overview

Readers can review the published sources and evidence referenced in this market overview.

Forecast Context

Base, estimated, and forecast years are shown to place the market outlook in context.

Current Publication Record

Each overview displays its report identifier and latest update date.

Report ID 24LS-8831
Base Year 2025
Forecast Period 2025–2034
Last Updated 26 Oct 2026
Inside the full report

What you can explore in this market report

A structured view of market size, forecast outlook, segmentation, regional dynamics, competitive activity, and the research framework behind this study.

01

Market Sizing & Forecasts

Review the market estimate, growth outlook, forecast direction, and key factors influencing future demand.

02

Segmentation Analysis

Understand the report’s defined segments, demand drivers, applications, end users, and market opportunities.

03

Regional Market View

Assess regional performance, selected country context, and factors shaping adoption across major markets.

04

Competition & Developments

Explore company profiles, market positioning, and selected developments relevant to the market landscape.

05

Market Dynamics & Trends

Review key demand drivers, challenges, emerging opportunities, technology shifts, and factors influencing market direction.

06

Research Methodology & Sources

Understand the report scope, market boundaries, research approach, and evidence referenced in the published market overview.